Core Viewpoint - Hanyu Pharmaceutical (300199.SZ) reported significant growth in its financial performance for the first half of 2025, indicating a strong recovery and operational efficiency [1] Financial Performance - The company achieved operating revenue of 549 million yuan, representing a year-on-year increase of 114.86% [1] - Net profit attributable to shareholders of the listed company was 145 million yuan, marking a turnaround from a loss to profit [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 123 million yuan [1] - Basic earnings per share stood at 0.16 yuan [1]

Core Viewpoint - Hanyu Pharmaceutical has received a marketing authorization for its product "Acetate Atosiban Injection" from the Vietnam Ministry of Health, indicating a significant expansion opportunity in the Southeast Asian market [1] Company Summary - Hanyu Pharmaceutical's product, Acetate Atosiban Injection, is a competitive antagonist of oxytocin receptors, specifically designed for pregnant women with indications of preterm labor [1] - The drug is intended to delay imminent preterm birth, demonstrating good clinical efficacy and minimal side effects [1] Industry Summary - The approval of Acetate Atosiban Injection in Vietnam highlights the growing demand for effective treatments in obstetrics, particularly for managing preterm labor [1] - This development may position Hanyu Pharmaceutical favorably within the pharmaceutical industry, especially in the context of expanding its product offerings in international markets [1]

Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. has received marketing authorization for its product Atosiban Acetate Injection from the Vietnam Ministry of Health, which is expected to enhance the company's international market presence and competitiveness [1][2]. Group 1: Drug Information - Drug Name: Atosiban Acetate Injection [1] - Registration Number: 690110326625 [1] - Specification: 5ml:37.5mg [1] - Manufacturer: Shenzhen Hanyu Pharmaceutical Co., Ltd. [1] - Validity of Approval: Until July 17, 2030 [1] Group 2: Drug Application - Atosiban is a competitive antagonist of oxytocin receptors, indicated for pregnant women with signs of preterm labor, aimed at delaying imminent preterm birth [1]. Group 3: Impact on the Company - The approval of Atosiban Acetate Injection is expected to enrich the company's overseas product pipeline and expand its international market [1]. - The company plans to actively promote the sales of this drug in overseas markets, enhancing its international brand influence and overall competitiveness [1].

Core Viewpoint - The report highlights the non-operating fund occupation and related transactions of Shenzhen Hanyu Pharmaceutical Co., Ltd., indicating significant amounts involved with various related parties [1][2]. Group 1: Non-operating Fund Occupation - The total non-operating fund occupation amounts to 771.55 million yuan, with specific contributions from various related parties [2]. - The report specifies that the non-operating fund occupation is categorized according to the "Stock Listing Rules" [2]. Group 2: Related Party Transactions - The report details the amounts of other receivables from subsidiaries and related parties, including 332.36 million yuan from Hanyu Health Technology and 200.62 million yuan from Hanyu Biological Technology [1][2]. - The total amount of related party transactions is broken down, showing a significant portion attributed to non-operating transactions [2].

【披露时间】 深圳翰宇药业股份有限公司 2025 年半年度报告全文 深圳翰宇药业股份有限公司 2025 年半年度报告全文 深圳翰宇药业股份有限公司 2025 年半年度报告 0 公司负责人曾少贵、主管会计工作负责人涂鸿鸿及会计机构负责人（会计主管人员）边彩云声明： 保证本半年度报告中财务报告的真实、准确、完整。 | 目录 | | --- | 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次半年报的董事会会议。 | 第一节 | 重要提示、目录和释义 | 1 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 7 | | 第三节 | 管理层讨论与分析 | 11 | | 第四节 | 公司治理、环境和社会 | 27 | | 第五节 | 重要事项 | 31 | | 第六节 | 股份变动及股东情况 | 41 | | 第七节 | 债券相关情况 | 46 | | 第八节 | 财务报告 | 48 | 公司在经营管理中可能面临的风险与应 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-038 深圳翰宇药业股份有限公司 关于醋酸阿托西班注射液获得越南药品上市许可的公告 注册号：690110326625 规格：5ml:37.5mg 药品生产商：深圳翰宇药业股份有限公司 批件有效期：2030年7月17日 二、药品的其他情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）收到越南 卫生部药品管理局下发的《药品注册证书》，公司产品"醋酸阿托西班注射液"的获 得了越南的上市许可，现将具体内容公告如下： 一、药品基本情况 药品名称：醋酸阿托西班注射液 药品英文名称： Atosiban Acetate Injection 2025年8月22日 阿托西班是一种催产素受体竞争性拮抗剂，适用于有早产指征的妊娠妇女，用 于推迟即将出现的早产，临床效果好，副作用小。 三、对公司的影响 公司醋酸阿托西班注射液具有良好的市场前景，其获得上市许可将进一步丰富 公司海外产品管线，拓宽公司海外市场，公司将积极推动该药品在海外市场的销售， 提高公司的 ...

| 非经营性资金占用 | 资金占 用方名 | 占用方与上 市公司的关 | 上市公司核 算的会计科 | 年期 2025 初占用资 | 2025 年度占 用累计发生 | 年度占 2025 用资金的利 | 年度偿 2025 还累计发生 | 年期末 2025 占用资金余 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 金额（不含利 | | | | 成原因 | | | | 称 | 联关系 | 目 | 金余额 | 息） | 息（如有） | 金额 | 额 | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他关联方及其附 | | | | | | | ...

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Group 1 - The assisted reproductive concept sector declined by 0.81%, ranking among the top declines in concept sectors, with major declines seen in companies like Fuyuan Pharmaceutical, Guangsheng Tang, and Wanfu Biology [1][2] - Among the 59 stocks in the assisted reproductive sector, 23 stocks saw price increases, with notable gains from Toukeng Life (up 7.45%), ST Xiangxue (up 4.55%), and Sichuan Shuangma (up 3.55%) [1][2] - The assisted reproductive sector experienced a net outflow of 2.015 billion yuan in main funds, with Guangsheng Tang leading the outflow at 297.48 million yuan [2][3] Group 2 - The top stocks with net outflows in the assisted reproductive sector included Guangsheng Tang, Hanyu Pharmaceutical, and Fuyuan Pharmaceutical, with outflows of 297.48 million yuan, 212.23 million yuan, and 164.10 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Wuchan Zhongda, Sichuan Shuangma, and Xianju Pharmaceutical, with inflows of 59.78 million yuan, 52.71 million yuan, and 36.47 million yuan respectively [2][4] - The overall trading activity in the assisted reproductive sector showed significant turnover rates, with Guangsheng Tang at 12.48% and Hanyu Pharmaceutical at 19.69% [2][3]

Market Performance - The monkeypox concept sector declined by 0.86%, ranking among the top losers in the market, with stocks like Fuyuan Pharmaceutical and Chengyi Pharmaceutical hitting the daily limit down [1] - Notable declines were observed in Wanfu Biology, Rejing Biology, and Zhongsheng Pharmaceutical, while 23 stocks within the sector saw price increases, with Toukeng Life, Chuangyuan Technology, and New Industry leading the gains at 7.45%, 3.96%, and 1.86% respectively [1][2] Capital Flow - The monkeypox concept sector experienced a net outflow of 1.624 billion yuan, with 61 stocks facing net outflows, and 11 stocks seeing outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 212.3 million yuan, followed by Fuyuan Pharmaceutical, Wanfu Biology, and Zhongsheng Pharmaceutical with net outflows of 164.1 million yuan, 126 million yuan, and 120 million yuan respectively [2][3] Top Gainers and Losers - The top gainers in the monkeypox concept sector included Toukeng Life, which saw a net inflow of 24.68 million yuan, and Guoyao Modern with a net inflow of 2.185 million yuan [4] - Conversely, the top losers included Hanyu Pharmaceutical, Fuyuan Pharmaceutical, and Wanfu Biology, which all faced significant capital outflows [2][3]